Oltipraz - Canopus BioPharma

Drug Profile

Oltipraz - Canopus BioPharma

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Wisconsin-Madison
  • Developer Canopus BioPharma
  • Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action DNA repair enzyme stimulants; Glutathione transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Mucositis

Most Recent Events

  • 23 Jun 2008 Canopus receives approval from the South African Medicines Control Council to begin a phase II trial with CB 1400 as a mucositis protective agent in patients with cancer
  • 19 Jun 2008 Preclinical trials in Cancer in USA (PO)
  • 19 Jun 2008 Preclinical pharmacodynamics data released by Canopus BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top